Greek startup Intelligencia has obtained €10.2 million ($12M) of Sequence A funding in a spherical led by European well being tech investor MTIP.
Earlier seed-round buyers, the Greek Large Pi Ventures and Synetro Group, additionally participated and have been joined by world skilled providers agency ZS.
Intelligencia may also accomplice with ZS, which is able to use its platform to assist speed up its skill to analysis illness and pipeline merchandise for shoppers.
WHAT IT DOES
Intelligencia’s mission is to carry modern therapies to sufferers sooner and with diminished danger by providing drug improvement firms machine studying predictions in regards to the trials they conduct and help their crucial decision-making course of.
The platform’s proprietary algorithms assess greater than 1.5B information factors throughout medical trial design, medical outcomes, drug biology, funding, regulatory pathways, sufferers, and medical publications to supply correct predictions and evaluation.
WHAT IT’S FOR
Intelligencia will use the funds for product improvement and the enlargement of its buyer dealing with groups. The startup can also be aiming to develop new partnerships with shoppers and companions to include extra information in its algorithms.
THE LARGER CONTEXT
Earlier this 12 months, French AI startup Iktos and drug discovery agency Facio Therapies introduced they’re collaborating to design therapy for the skeletal muscle losing situation facioscapulohumeral dystrophy (FSHD). Underneath the settlement, Iktos will apply its de novo ligand and structure-based generative modelling AI applied sciences in one among Facio’s drug discovery programmes.
In the meantime Israeli startup CytoReason just lately introduced a collaboration with Swiss multinational, Ferring Prescription drugs, to ascertain new therapies for inflammatory bowel illness (IBD). The partnership is pairing Ferring’s medical experience with CytoReason’s AI platform to construct cell-centred illness fashions.
ON THE RECORD
Vangelis Vergetis, Intelligencia cofounder, stated: “We already work with a number of biopharmaceutical firms as they assess the danger of medical improvement and intention to extend the productiveness of their R&D efforts, together with by accessing exterior innovation. This spherical will primarily go in the direction of constructing our customer-facing groups within the US and Europe, in addition to persevering with to spend money on our information and AI capabilities.”
Dimitrios Skaltsas, Intelligencia cofounder, added: “Intelligencia has been pioneering the applying of knowledge science options in the direction of assessing and mitigating dangers in drug improvement. That is solidly based on expertly curated information and proprietary ontologies which have enabled us to generate one of many world’s richest data graphs in our house. We are actually really excited to be partnering with ZS.”
Judith Kulich, ZS principal, stated: “This strategic partnership supplies intensive advantages to our shoppers and companions. By way of a sturdy understanding of the drivers behind medical and regulatory success, in addition to predictive modelling of molecules and packages most certainly to achieve success, we are going to information our shoppers to spend money on these areas most certainly to understand worth for sufferers and convey about tangible impression. Finally, this can scale back danger in drug improvement and enhance the productiveness of analysis and improvement.”